These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24445279)

  • 1. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation.
    Duivenvoorden R; Tang J; Cormode DP; Mieszawska AJ; Izquierdo-Garcia D; Ozcan C; Otten MJ; Zaidi N; Lobatto ME; van Rijs SM; Priem B; Kuan EL; Martel C; Hewing B; Sager H; Nahrendorf M; Randolph GJ; Stroes ES; Fuster V; Fisher EA; Fayad ZA; Mulder WJ
    Nat Commun; 2014; 5():3065. PubMed ID: 24445279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.
    Murphy AJ; Funt S; Gorman D; Tall AR; Wang N
    Circ Res; 2013 Jun; 113(1):e1-e9. PubMed ID: 23613182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Design of Lovastatin-Loaded Spherical Reconstituted High Density Lipoprotein for Efficient and Safe Anti-Atherosclerotic Therapy.
    Jiang C; Qi Z; Tang Y; Jia H; Li Z; Zhang W; Liu J
    Mol Pharm; 2019 Jul; 16(7):3284-3291. PubMed ID: 31117743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Anti-Atherosclerotic Efficacy of pH-Responsively Releasable Ganglioside GM3 Delivered by Reconstituted High-Density Lipoprotein.
    Rong T; Wei B; Ao M; Zhao H; Li Y; Zhang Y; Qin Y; Zhou J; Zhou F; Chen Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
    Alaarg A; Senders ML; Varela-Moreira A; Pérez-Medina C; Zhao Y; Tang J; Fay F; Reiner T; Fayad ZA; Hennink WE; Metselaar JM; Mulder WJM; Storm G
    J Control Release; 2017 Sep; 262():47-57. PubMed ID: 28700897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plaque-hyaluronidase-responsive high-density-lipoprotein-mimetic nanoparticles for multistage intimal-macrophage-targeted drug delivery and enhanced anti-atherosclerotic therapy.
    Zhang M; He J; Jiang C; Zhang W; Yang Y; Wang Z; Liu J
    Int J Nanomedicine; 2017; 12():533-558. PubMed ID: 28144137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.
    Hossaini Nasr S; Rashidijahanabad Z; Ramadan S; Kauffman N; Parameswaran N; Zinn KR; Qian C; Arora R; Agnew D; Huang X
    Nanoscale; 2020 May; 12(17):9541-9556. PubMed ID: 32314997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Human-Like Advanced Coronary Plaques in Low-Density Lipoprotein Receptor Knockout Pigs and Justification for Statin Treatment Before Formation of Atherosclerotic Plaques.
    Li Y; Fuchimoto D; Sudo M; Haruta H; Lin QF; Takayama T; Morita S; Nochi T; Suzuki S; Sembon S; Nakai M; Kojima M; Iwamoto M; Hashimoto M; Yoda S; Kunimoto S; Hiro T; Matsumoto T; Mitsumata M; Sugitani M; Saito S; Hirayama A; Onishi A
    J Am Heart Assoc; 2016 Apr; 5(4):e002779. PubMed ID: 27091180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes.
    Katsuki S; Matoba T; Nakashiro S; Sato K; Koga J; Nakano K; Nakano Y; Egusa S; Sunagawa K; Egashira K
    Circulation; 2014 Feb; 129(8):896-906. PubMed ID: 24305567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamically enhancing plaque targeting via a positive feedback loop using multifunctional biomimetic nanoparticles for plaque regression.
    Jiang C; Qi Z; He W; Li Z; Tang Y; Wang Y; Huang Y; Zang H; Yang H; Liu J
    J Control Release; 2019 Aug; 308():71-85. PubMed ID: 31295543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A
    Otsuka F; Zhao X; Trout HH; Qiao Y; Wasserman BA; Nakano M; Macphee CH; Brandt M; Krug-Gourley S; Guo L; Ladich ER; Cheng Q; Davis HR; Finn AV; Virmani R; Kolodgie FD
    Atherosclerosis; 2017 Dec; 267():78-89. PubMed ID: 29101839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoproteins may offer a more promising route to statin therapy.
    Coaker H
    Future Cardiol; 2014 Mar; 10(2):164. PubMed ID: 24883441
    [No Abstract]   [Full Text] [Related]  

  • 13. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques.
    Zhao Y; Gao H; He J; Jiang C; Lu J; Zhang W; Yang H; Liu J
    J Control Release; 2018 Aug; 283():241-260. PubMed ID: 29885417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in Apo-E deficient mice.
    Cho KH
    J Atheroscler Thromb; 2009 Jun; 16(3):217-29. PubMed ID: 19638715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis.
    Chen W; Vucic E; Leupold E; Mulder WJ; Cormode DP; Briley-Saebo KC; Barazza A; Fisher EA; Dathe M; Fayad ZA
    Contrast Media Mol Imaging; 2008; 3(6):233-42. PubMed ID: 19072768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute perioperative-stress-induced increase of atherosclerotic plaque volume and vulnerability to rupture in apolipoprotein-E-deficient mice is amenable to statin treatment and IL-6 inhibition.
    Janssen H; Wagner CS; Demmer P; Callies S; Sölter G; Loghmani-khouzani H; Hu N; Schuett H; Tietge UJ; Warnecke G; Larmann J; Theilmeier G
    Dis Model Mech; 2015 Sep; 8(9):1071-80. PubMed ID: 26092124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques.
    Fotakis P; Kothari V; Thomas DG; Westerterp M; Molusky MM; Altin E; Abramowicz S; Wang N; He Y; Heinecke JW; Bornfeldt KE; Tall AR
    Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):e253-e272. PubMed ID: 31578081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal injection improves the uptake of nanoparticle-labeled high-density lipoprotein to atherosclerotic plaques compared with intravenous injection: a multimodal imaging study in ApoE knockout mice.
    Jung C; Kaul MG; Bruns OT; Dučić T; Freund B; Heine M; Reimer R; Meents A; Salmen SC; Weller H; Nielsen P; Adam G; Heeren J; Ittrich H
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):303-11. PubMed ID: 24357264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models.
    Pérez-Medina C; Binderup T; Lobatto ME; Tang J; Calcagno C; Giesen L; Wessel CH; Witjes J; Ishino S; Baxter S; Zhao Y; Ramachandran S; Eldib M; Sánchez-Gaytán BL; Robson PM; Bini J; Granada JF; Fish KM; Stroes ES; Duivenvoorden R; Tsimikas S; Lewis JS; Reiner T; Fuster V; Kjær A; Fisher EA; Fayad ZA; Mulder WJ
    JACC Cardiovasc Imaging; 2016 Aug; 9(8):950-61. PubMed ID: 27236528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.